These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2402065)

  • 1. [Lambert-Eaton myasthenic syndrome].
    Sahashi K
    Nihon Rinsho; 1990 Jul; 48(7):1477-82. PubMed ID: 2402065
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic approaches to Lambert-Eaton myasthenic syndrome in the intra-individual comparison.
    Jost WH; Mielke U; Schimrigk K
    Wien Klin Wochenschr; 1991; 103(20):629-32. PubMed ID: 1763511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy.
    Cooke JD; Hefter H; Brown SH; Toyka KV; Freund HJ
    Electromyogr Clin Neurophysiol; 1994 Mar; 34(2):87-93. PubMed ID: 8187683
    [No Abstract]   [Full Text] [Related]  

  • 4. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
    McEvoy KM; Windebank AJ; Daube JR; Low PA
    N Engl J Med; 1989 Dec; 321(23):1567-71. PubMed ID: 2555713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful alternate day guanidine therapy following guanidine-induced neutropenia in the Lambert-Eaton myasthenic syndrome.
    Silbert PL; Hankey GJ; Barr AL
    Muscle Nerve; 1990 Apr; 13(4):360-1. PubMed ID: 2355949
    [No Abstract]   [Full Text] [Related]  

  • 6. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome before and after 3,4-diaminopyridine.
    Sadeh M; River Y; Argov Z
    Muscle Nerve; 1997 Jun; 20(6):735-9. PubMed ID: 9149081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome.
    Chaudhry V; Watson DF; Bird SJ; Cornblath DR
    Muscle Nerve; 1991 Dec; 14(12):1227-30. PubMed ID: 1662773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.
    Tim RW; Massey JM; Sanders DB
    Ann N Y Acad Sci; 1998 May; 841():823-6. PubMed ID: 9668336
    [No Abstract]   [Full Text] [Related]  

  • 9. Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome.
    Oh SJ; Kim DS; Kwon KH; Tseng A; Mussell H; Claussen GC
    Ann N Y Acad Sci; 1998 May; 841():827-31. PubMed ID: 9668337
    [No Abstract]   [Full Text] [Related]  

  • 10. The association of systemic lupus erythematosus and Lambert-Eaton myasthenic syndrome.
    Deodhar A; Norden J; So Y; Bennett R
    J Rheumatol; 1996 Jul; 23(7):1292-4. PubMed ID: 8823710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The treatment of the Eaton-Lambert myasthenic syndrome with 3,4-diaminopyridine].
    Casanova B; Vílchez JJ; Rubio P
    Rev Clin Esp; 1993 Apr; 192(7):354-5. PubMed ID: 8388576
    [No Abstract]   [Full Text] [Related]  

  • 12. A treatment algorithm for Lambert-Eaton myasthenic syndrome.
    Newsom-Davis J
    Ann N Y Acad Sci; 1998 May; 841():817-22. PubMed ID: 9668335
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
    Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM
    Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current therapy of the Lambert-Eaton myasthenic syndrome.
    Lundh H; Nilsson O; Rosén I
    Prog Brain Res; 1990; 84():163-70. PubMed ID: 2267294
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of firing rate on neuromuscular jitter in Lambert-Eaton myasthenic syndrome.
    Sanders DB
    Muscle Nerve; 1992 Feb; 15(2):256-8. PubMed ID: 1549148
    [No Abstract]   [Full Text] [Related]  

  • 16. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
    Quartel A; Turbeville S; Lounsbury D
    Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lambert-Eaton myasthenic syndrome: response to treatment with 3,4-diaminopyridine].
    Morata C; Alfaro A; Chumillas MJ; Montalar J
    Med Clin (Barc); 1995 Feb; 104(4):156. PubMed ID: 7898163
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment for Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003279. PubMed ID: 15846654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 fiber predominance in Lambert-Eaton myasthenic syndrome.
    Squier M; Chalk C; Hilton-Jones D; Mills KR; Newsom-Davis J
    Muscle Nerve; 1991 Jul; 14(7):625-32. PubMed ID: 1922168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cyclosporin A in the treatment of Eaton-Lambert myasthenic syndrome].
    Yuste Ara JR; Beloqui Ruiz O; Artieda Gonzalez-Granda J; Herrero Santos JI; De la Peña Fernandez A; Prieto Valtueña J
    An Med Interna; 1996 Jan; 13(1):25-6. PubMed ID: 8679819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.